A Mixed Bag

Times are still difficult for many biotechs, but Ed Silverman writes at Pharmalot that the situation is actually a bit variable. Drawing on a report from consulting firm BDO, Silverman notes that biotech firms spent slightly more on R&D in 2011 than in 2010, though he adds that while large biotechs reported about 33 percent increase in revenue, smaller biotechs have not seen such large gains, reporting 12 percent decline in revenue.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.